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Abstract
Chikungunya virus (CHIKV) is a mosquito-transmitted alphavirus that causes global epidemics of a debilitating polyarthritis
in humans. As there is a pressing need for the development of therapeutic agents, we screened 230 new mouse anti-CHIKV
monoclonal antibodies (MAbs) for their ability to inhibit infection of all three CHIKV genotypes. Four of 36 neutralizing MAbs
(CHK-102, CHK-152, CHK-166, and CHK-263) provided complete protection against lethality as prophylaxis in highly
susceptible immunocompromised mice lacking the type I IFN receptor (Ifnar2/2) and mapped to distinct epitopes on the E1
and E2 structural proteins. CHK-152, the most protective MAb, was humanized, shown to block viral fusion, and require Fc
effector function for optimal activity in vivo. In post-exposure therapeutic trials, administration of a single dose of a
combination of two neutralizing MAbs (CHK-102+CHK-152 or CHK-166+CHK-152) limited the development of resistance and
protected immunocompromised mice against disease when given 24 to 36 hours before CHIKV-induced death. Selected
pairs of highly neutralizing MAbs may be a promising treatment option for CHIKV in humans.
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Introduction
Chikungunya virus (CHIKV) infection causes a severe febrile
illness in humans that is characterized by a debilitating polyar-
thritis, which can persist for months and cause significant
morbidity [1,2]. There are three genotypes of CHIKV: Asian,
East/Central/South African (ECSA), and West African [3–5],
with 95.2 to 99.8% amino acid identity [4]. The CHIKV strains
from the recent epidemics belong to the ECSA genotype and have
affected millions in Africa and the Indian subcontinent [3,6].
Imported cases in the United States and outbreaks in Europe
highlight the threat of CHIKV to developed countries [7].
Currently, there are no approved vaccines or therapeutics for
CHIKV [8].
CHIKV is an enveloped alphavirus of the Togaviridae family that
enters cells via receptor-mediated internalization and a low pH-
triggered type II membrane fusion event in early endosomes. The
mature virion is comprised of three structural proteins: a
nucleocapsid protein and two glycoproteins, E1 and E2, where
E2 functions in attachment to cells and E1 participates in virus
fusion. Each 700 A˚ CHIKV virion contains 240 copies of the
envelope and capsid proteins, which are arranged in T = 4 quasi-
icosahedral symmetry. E1-E2 heterodimers assemble into 80
trimeric spikes on the virus surface [9]. X-ray crystallographic
structures of the precursor pE3-E2-E1, mature E2-E1, and E1
proteins [10–13] have elucidated the architecture of the glycopro-
tein shell. The E1 ectodomain consists of three domains. Domain I
(DI) is located between DII and DIII, the latter of which adopts an
immunoglobulin-like fold. The fusion peptide is located at the
distal end of DII. E1 monomers lie at the base of the surface spikes
and form a trimer around each of the icosahedral axes. E2
localizes to a long, thin leaf-like structure on the top of the spike.
The mature E2 protein contains three domains with immuno-
globulin-like folds: the N-terminal domain A, located at the center;
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domain B at the tip; and the C-terminal domain C, located
proximal to the viral membrane.
Mouse models have been developed for CHIKV infection.
Newborn outbred and inbred mice are vulnerable to severe
CHIKV infection with viral replication observed in muscle, joint,
and skin [14,15]. Adult mice with defects in type I interferon
signaling (Ifnar2/2 mice) develop lethal disease, with muscle, joint,
and skin appearing as the primary sites of infection [15]. CHIKV
infection of juvenile C57BL/6 mice by a subcutaneous route
results in metatarsal foot swelling with histological evidence of
arthritis, tenosynovitis and myositis [16,17].
Passive transfer of MAbs or immune sera can protect animals
against infection of alphaviruses including Sindbis (SINV), Semliki
Forest (SFV), and Venezuelan equine encephalitis (VEEV) viruses
[18–25]. Immune c-globulin from human donors in the conva-
lescent phase of CHIKV infection exhibited neutralizing activity in
vitro and had partial therapeutic efficacy in Ifnar2/2 and neonatal
wild type mice when administered up to 24 hours after infection
[26]. Although mouse and human MAbs that neutralize CHIKV
infection have been reported [27,28], their post-exposure efficacy
against lethal infection in vivo has not been clearly established [29].
Here, we investigated the molecular basis of antibody-mediated
neutralization of CHIKV using a panel of 230 newly generated,
cloned MAbs. CHK-152 protected mice against CHIKV-induced
mortality and disease. The inclusion of a second MAb (CHK-166
or CHK-102) prevented the emergence of viral resistance and
extended the treatment window in Ifnar2/2 mice up to 24 to
36 hours prior to death of the animals. Our results suggest that
combination therapy with selected neutralizing MAbs has
potential for treatment of CHIKV infection in humans.
Results
Generation of MAbs
We generated a panel of neutralizing MAbs against CHIKV as
a first step towards a possible therapy in humans. We infected
adult C57BL/6 mice deficient for interferon regulatory factor 7
(Irf72/2) with 104 PFU of the La Reunion 2006 OPY-1 strain of
CHIKV (CHIKV-LR); these mice were boosted with CHIK virus-
like particles [30], soluble recombinant CHIKV E2 protein, or live
CHIKV-LR. We immunized Irf72/2 rather than wild type (WT)
mice, as CHIKV replicated to higher titers, induced stronger
neutralizing antibody responses, yet did not cause lethal infection
in these innate immune-deficient animals ([31], and data not
shown). We screened four independent myeloma cell-splenocyte
fusions for binding of hybridoma supernatants to CHIKV-LR
infected cells (Fig. S1) and cloned 230 CHIKV-specific MAbs for
further analysis (Table S1 in Text S1). Using a single endpoint
neutralization assay, we identified 36 MAbs with inhibitory
activity against infection of CHIKV-LR in BHK21-15 cells (data
not shown).
Neutralizing activity
To assess the inhibitory potential of our anti-CHIKV MAbs
against the homologous CHIKV-LR and representative strains
from the Asian and West African genotypes (RSU1 and IbH35
respectively), we performed focus reduction neutralization tests
(FRNTs) on Vero cells. We determined the concentration of MAb
that reduced the number of foci of infection by 50 or 90% (EC50
and EC90 values, Fig. 1A and B, and Table 1). CHK-152 was
the most strongly neutralizing MAb we identified; 3 and 15 ng/ml
of this MAb prevented 50 and 90% of CHIKV infection against all
three CHIKV genotypes (Fig. 1C). Ten other MAbs inhibited
CHIKV infection with EC50 values of ,10 ng/ml against all
three genotypes, and many others inhibited all three strains
similarly, with a few exceptions. For example, CHK-9 failed to
neutralize the Asian strain to the same extent as the West African
or La Reunion (ECSA genotype) strains (Fig. 1D), whereas CHK-
151 inhibited infection of the Asian strain better than the others
(Table 1). Also, for reasons that are unclear, some neutralizing
MAbs (e.g., CHK-143, CHK-264, and CHK-269) were incapable
of inhibiting all viruses (EC90.10,000 ng/ml) in this assay, even
at high MAb concentrations.
We speculated that some MAbs might show cell type-dependent
neutralization if they blocked attachment to cell type-specific
factors. To test this hypothesis, we assessed MAb neutralization of
CHIKV-LR infection in cells of another species, NIH 3T3 mouse
fibroblasts (Table 1). For most MAbs, the EC50 values were
comparable to those achieved with Vero cells. However, two
MAbs (CHK-96 and CHK-176) showed a 12 to 250-fold
reduction (P,0.05) in neutralizing activity on NIH 3T3 compared
to Vero cells; although further study is warranted, these MAbs
may block a step in the entry pathway that varies among different
cell types.
Prophylaxis studies
To evaluate whether neutralizing MAbs protect against
CHIKV infection in vivo, we initially used a stringent test model:
prevention of lethal infection in immunodeficient Ifnar2/2
C57BL/6 mice. One hundred micrograms of 14 different MAbs
with strong, modest, or poor neutralizing activity were adminis-
tered to Ifnar2/2 mice one day prior to CHIKV-LR infection. As
seen previously [15], all Ifnar2/2 mice died by day 4 after infection
when treated with saline or a negative control MAb (Fig. 2A, and
data not shown). Strongly neutralizing (e.g., CHK-102, CHK-152,
and CHK-263) and one moderately inhibitory (CHK-166) MAb
protected 100% of mice from lethal infection (P,0.0001). In
comparison, and somewhat surprisingly, CHK-95, a potently
neutralizing MAb of the same IgG2c isotype, protected only 12%
of mice from death. The other MAbs tested conferred interme-
diate levels of protection (Fig. 2A). Thus, although several strongly
neutralizing MAbs prevented against lethal CHIKV infection in
Author Summary
Chikungunya virus (CHIKV) is a mosquito-transmitted
alphavirus that causes outbreaks of polyarthritis in
humans, and is currently a threat to spread to the United
States due to the presence of its mosquito vector, Aedes
albopictus. At present, there is no licensed human vaccine
or therapeutic available to protect against CHIKV infection.
The primary goal of this study was to develop an antibody-
based therapeutic agent against CHIKV. To do this, we
developed a panel of 230 new mouse anti-CHIKV MAbs
and tested them for their ability to neutralize infection of
different CHIKV strains in cell culture. We identified 36
MAbs with broad neutralizing activity, and then tested
several of these for their ability to protect immunocom-
promised Ifnar2/2 mice against lethal CHIKV infection. In
post-exposure therapeutic trials, administration of a single
dose of a combination of two neutralizing MAbs limited
the development of resistance and protected Ifnar2/2
mice against disease even when given just 24 to 36 hours
before CHIKV-induced death. Analogous protection
against CHIKV-induced arthritis was seen in a disease
model in wild type mice. Our data suggest that pairs of
highly neutralizing MAbs may be a therapeutic option
against CHIKV infection.
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Ifnar2/2 mice, in vitro neutralization activity per se did not directly
correlate with protection. To define the relative potency of the
four MAbs that completely prevented lethal disease, we admin-
istered a lower (10 mg) dose. Whereas CHK-152 and CHK-263
still protected most mice from lethal infection, CHK-102 and
CHK-166 protected to a lesser degree or only prolonged survival
(Fig. 2B). Consistent with their ability to protect against lethal
infection, passive transfer of CHK-102, CHK-152, CHK-166, and
CHK-263 MAbs all markedly reduced viral loads in serum,
spleen, liver, muscle, and brain at 48 hours after infection relative
to a non-binding isotype control (DENV1-E98) MAb (Fig. 2C–
G). The level of protection afforded by CHK-102, CHK-152,
CHK-166, and CHK-263 MAbs, however, did not correlate
directly with their binding strength to CHIKV surface glycopro-
teins (Fig. S2).
Although a stringent test of MAb protection, CHIKV-infected
Ifnar2/2 mice do not develop the arthritis observed in humans. To
evaluate this, we utilized a WT C57BL/6 mouse model in which
inoculation of CHIKV into the footpad results in localized swelling
and induction of arthritis and fasciitis within the foot and ankle
[16,17], although infection does not cause lethality. Pretreatment
of mice with either 100 mg of CHK-102 or CHK-152 completely
protected against CHIKV-induced swelling, compared to control
animals, which developed clinically apparent swelling (data not
shown). While CHIKV infected control animals developed
inflammatory arthritis in the ankle and foot, CHK-102 or
CHK-152 MAb treated animals had normal appearing joint
tissues (Fig. 2H).
Mechanism of neutralization
Antibody neutralization of enveloped viruses can occur by
inhibiting attachment, internalization, and/or fusion [32,33]. To
determine how many of our most protective MAbs inhibited
infection in cell culture, we performed pre- and post-attachment
neutralization assays [34,35]. Anti-CHK MAbs were incubated
with CHIKV before or after virus binding to cells, and infection
was measured. As expected, all MAbs efficiently neutralized
infection when pre-mixed with virus (Fig. 3A). While CHK-102,
CHK-152, CHK-166, and CHK-263 also inhibited CHIKV
infection when added after virus adsorption to the cell surface,
Figure 1. Profile of neutralizing MAbs against CHIKV. A. Examples of MAb neutralization as judged by a reduction in the number of FFU using
the Biospot Macroanalyzer. Rows 2 to 12 going across represent decreasing (3-fold) concentrations of CHK-152 or the negative control DENV1-E98
MAb. Column 1 shows infection in the absence of MAb. B. Increasing concentrations of CHK-95, CHK-102, CHK-166, CHK-187, or CHK-263 were mixed
with 100 to 150 FFU of CHIKV-LR for one hour at 37uC and Vero cells were infected. Neutralization was determined by FFU assay. C–D. CHK-152 (C) or
CHK-9 (D) was mixed with CHIKV-LR (East, Central and South African genotype), CHIKV-RSUI (Asian genotype), or CHIKV IbH35 (West African
genotype) for one hour at 37uC and Vero or NIH 3T3 cells were infected as indicated. Neutralization was determined by FFU assay. Data in this Figure
is pooled from three independent experiments performed in duplicate or triplicate. All error bars represent the standard deviations.
doi:10.1371/journal.ppat.1003312.g001
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suggesting that at least part of their blocking activity was at a post-
attachment step, differences in the extent of neutralization were
noted in this context for several MAbs. CHK-152 completely
neutralized all CHIKV virions without a resistant fraction when
added post-attachment. When studies were repeated with eight
other neutralizing MAbs that showed pre-exposure protection in
vivo, no other MAb inhibited infection completely when added
after virus adsorption to the cell. As expected, an isotype control
MAb (DENV1-E98) and a non-neutralizing anti-CHK MAb
(CHK-84) had no inhibitory effects in this assay (Fig. S3).
Blockade of viral fusion
Since CHK-152 neutralized infection efficiently at a post-
attachment step, we investigated whether it blocked fusion using a
viral fusion from without (FFWO) assay [36]. CHIKV was
adsorbed to Vero cell monolayers on ice and then treated with
MAbs. Fusion at the plasma membrane was triggered after a brief
exposure to low pH buffered medium at 37uC. Subsequently, cells
were incubated in the presence of 20 mM NH4Cl to prevent
CHIKV fusion via canonical endosomal pathways. As expected, at
14 hours after initial treatment, CHIKV infection was not
Figure 2. Efficacy of anti-CHIKV MAb prophylaxis. A. Six to eight week-old Ifnar2/2 C57BL/6 mice were passively transferred 100 mg of the
indicated MAbs via an i.p. injection one day before infection with 10 FFU of CHIKV-LR via a s.c. route. The percentage and number of surviving mice
were as follows: DENV1-E98 (0%, 0 of 9), CHK-88 (62.5%; 5 of 8), CHK-95 (12.5%; 1 of 8), CHK-98 (28.6%; 2 of 7), CHK-102 (100%; 8 of 8), CHK-124 (75%;
6 of 8), CHK-151 (87.5%; 7 of 8), CHK-152 (100%; 8 of 8), CHK-155 (85.7%; 6 of 7), CHK-165 (28.6%; 2 of 7), CHK-166 (100%; 8 of 8), CHK-175 (75%; 6 of
8), CHK-187 (50%; 4 of 8), CHK-263 (100%; 8 of 8), or CHK-266 (0%; 0 of 8). MAbs italicized in red in the Figure provided 100% protection. B. Ifnar2/2
mice were passively transferred 10 mg of MAb via an i.p. injection one day before infection with 10 FFU of CHIKV-LR via a s.c. route. The percentage
and number of surviving mice were as follows: DENV1-E98 (0%; 0 of 7), CHK-102 (12.5%; 1 of 8), CHK-152 (83%; 10 of 12), CHK-166 (0%; 0 of 12), or
CHK-263 (73%; 8 of 11). For (A) and (B) the survival curves were constructed from data of at least two independent experiments. All anti-CHK MAbs
provided statistically significant protection in the percentage of surviving animals or mean survival time compared to the control DENV1-E98 MAb
(P,0.05). C–G. Viral burden in MAb-treated Ifnar2/2mice. Animals were passively transferred 100 mg of the indicated MAbs (CHK-102, CHK-152, CHK-
166, CHK-263, or isotype control DENV1-E98) via an i.p. injection one day before infection with 10 FFU of CHIKV-LR via a s.c. route. Two days later,
viremia (C) and tissues (D, spleen; E, liver; F, muscle; and G, brain) were harvested and infectious virus was titrated by focus-forming assay. Results are
pooled from two independent experiments (n=4 mice per group). The dashed line indicates the limit of detection of the assay and the solid bar
indicates the median values. All viral burden results with CHK-102, CHK-152, CHK-166, and CHK-263 were statistically different (P,0.02) from those
obtained with DENV1-E98, as analyzed by the Mann-Whitney test. H. Four week-old female WT C57BL/6 mice were sham-treated or administered
100 mg of CHK-102 or CHK-152 via an i.p. route. 24 hours later, mice were infected with 100 PFU of CHIKV-SL 15649 and at day 10, virus-induced
pathology in the foot and ankle joint was assessed. (Outer left) Sham-infected, (middle left) CHIKV infected and sham-treated, (middle right) CHIKV-
infected and CHK-102 treated, and (outer right) CHIKV infected and CHK-152 treated. Shown are representative images after hematoxylin and eosin
staining from at least 3 mice per group at 1006 magnification. Yellow and green arrows indicate regions of inflammation or normal joints,
respectively.
doi:10.1371/journal.ppat.1003312.g002
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Figure 3. Mechanism of neutralization by CHIKV MAbs. A. Pre- and post-attachment inhibition assays. Vero cells were pre-chilled to 4uC and
100 FFU of CHIKV-LR was added to each well for one hour. After extensive washing at 4uC, the indicated MAbs were added for one hour at 4uC, and
then the FRNT protocol was completed (black lines, Post). In comparison, a standard pre-incubation FRNT with all steps performed at 4uC is shown for
reference. Virus and MAb are incubated together for one hour at 4uC, prior to addition to cells (red lines, Pre). Data shown are representative of three
experiments performed in duplicate with error bars representing standard deviation. B–C. FFWO assay. CHIKV was incubated with Vero cells at 4uC to
allow virus attachment. Free virus was removed after washing and 50 mg/ml of the indicated MAbs (including DENV1-E98, a negative control MAb)
were added at 4uC. Viral fusion at the plasma membrane was induced after a brief exposure to a low pH buffer. After pH normalization, cells were
cultured for 14 hours in the presence of NH4Cl to inhibit infection through the endosomal pathway. Cells were analyzed for infection by staining with
an anti-E2 MAb. Representative histograms are shown (B) and the data was pooled from four independent experiments for statistical analysis (C). For
simplicity of display, not all of the MAbs included in the summary graph are shown by flow cytometry analysis. Asterisks indicate values that are
statistically different (P,0.05) from the control MAb. Error bars represent standard deviations. Note low pH-triggered viral fusion at the plasma
membrane is an inefficient process with only 10 to 20% of cells becoming infected even when a high MOI was used. D–E. Viral membrane fusion with
liposomes. Fusion of pyrene-labeled CHIKV was measured at pH 4.7 (37uC) using liposomes consisting of phosphatidylcholine, phosphatidyleth-
anolamine, sphingomyelin, and cholesterol in a molar ratio of (1/1/1/1.5), as described in the Methods. (D) Curve a, no MAb; curve b, 0.1 nM CHK-152;
curve c, 1 nM CHK-152; curve d, 10 nM CHK-152. (E) Extent of fusion (average value between 50 to 60 seconds post acidification) at increasing
concentrations of MAb. Black bars, CHK-152; white bar, isotype control (MAb 0031, only included at 10 nM concentration). All fusion measurements
were performed at least three independent times.
doi:10.1371/journal.ppat.1003312.g003
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observed when adsorbed virus was incubated at neutral pH
(Fig. 3B). In comparison, in the absence of MAb or in the
presence of a control MAb, a short exposure of cell surface-
adsorbed virus to acidic pH resulted in infection and CHIKV-
antigen positive cells. Notably, CHK-152 completely inhibited
(P,0.0001) plasma membrane fusion and infection, whereas other
anti-CHIKV neutralizing MAbs showed significant yet incomplete
inhibition in this assay (Fig. 3B and C). These studies suggest that
CHK-152 efficiently neutralizes infection by preventing the
structural changes on the virion necessary for viral fusion with
host cell membranes.
We utilized a model liposome fusion assay with pyrene-labeled
virus [37,38] to confirm these results. Pyrene-labeled CHIKV was
pre-incubated with different concentrations of MAb, mixed with
liposomes at 37uC, and fusion was triggered by addition of a low-
pH buffer [37]. In the absence of MAb or in the presence of
10 nM (1.5 mg/ml) of a non-binding control MAb, fusion was
complete within seconds of acidification. In contrast, pre-
incubation of virus with increasing doses of CHK-152 inhibited
fusion (Fig. 3D and E). Thus, CHK-152 can block low-pH-
induced fusion of virus with liposomes.
The effector functions of CHK-152 contribute to
protection in vivo
To define additional mechanisms by which our most strongly
protective MAb (CHK-152) conferred protection in vivo, we
generated a chimeric mouse-human CHK-152 (ch-CHK-152) as
well as an aglycosyl variant (ch-CHK-152 N297Q) that lacks the
ability to engage C1q or Fc-c receptors; this mutation does not
affect the ability to bind the neonatal Fc receptor (FcRn) or half-
life of antibody in mouse serum [39]. The affinity of ch-CHK-152
and ch-CHK-152 N297Q binding to purified pE2-E1 was
measured by surface plasmon resonance (SPR) and compared to
the parent murine MAb. Notably, ch-CHK-152, ch-CHK-152
N297Q, and the murine CHK-152 all had similar affinity (KD of 3
to 4 nM) (Fig. 4A and data not shown) and neutralizing activity in
cell culture (Fig. 4B). As expected, ch-CHK-152 N297Q failed to
bind efficiently to soluble Fc-c receptors or C1q (Fig. 4C).
We transferred ch-CHK-152 and ch-CHK152 N297Q to
Ifnar2/2 mice prior to infection. Although high doses (100 mg) of
ch-CHK-152 and ch-CHK-152 N297Q provided similar protec-
tion against CHIKV infection (data not shown), lower doses
(10 mg) of the aglycosyl variant were less protective; whereas 62%
of the mice receiving ch-CHK152 N297Q survived, all Ifnar2/2
mice given ch-CHK-152 MAb remained alive (Fig. 4D, P,0.05).
When parallel studies were performed with WT C57BL/6 mice
and MAb was administered 18 hours after infection, ch-CHK-152
N297Q also provided less protection against arthritis compared to
ch-CHK-152 (Fig. 4E). These data suggest that the Fc effector
interactions contribute to the potency of CHK-152 in mice.
Humanization of CHK-152
We humanized CHK-152 as a first step towards a MAb
therapeutic (see Text S1). The affinity for pE2-E1 and neutral-
izing activity of the hu-CHK-152 were similar to mouse CHK-152
(Fig. S4A and B). Hu-CHK-152 also protected Ifnar2/2 mice
(P.0.0001) when a single dose (10 or 100 mg) was administered
one day before infection (Fig. S4C).
Therapeutic studies
To define the therapeutic potential of our most protective
MAbs, a single dose (100 mg) was administered to Ifnar2/2 mice
24 hours after CHIKV infection (Fig. 5A). Whereas CHK-152
and 166 protected 58% and 63% of mice from death, respectively
(P,0.0001), CHK-263 and CHK-102 had less activity although
both MAbs increased the median survival time (7 days versus 4
days with the control DENV1-E98 MAb, P,0.0006). Adminis-
tration of CHK-152 at 12 or 18 hours post infection also protected
WT mice from CHIKV-induced swelling and arthritis (Fig. 5B
and Fig. 4E).
We next tested the activity of combinations of the most
protective neutralizing MAbs in Ifnar2/2 mice. Remarkably,
administration of 50 mg each (100 mg total dose) of CHK-
102+CHK-152, CHK-263+CHK-152, or CHK-166+CHK-152
at 24 hours post infection completely prevented mortality in all
animals (Fig. 5A, P,0.0001 for MAb combinations). This
observation was not true for all MAb combinations, as adminis-
tration of 50 mg each of CHK-102+CHK-263 provided substan-
tially less protection with a 14% survival rate. We then performed
a more stringent test in which 100 mg each (200 mg total) of our
most protective combinations was delivered as a single dose at
48 hours post-infection (Fig. 5C). Treatment with CHK-
102+CHK-152 or CHK-166+CHK-152 protected 62% of the
Ifnar2/2 mice (P,0.003) and the combination of CHK-
263+CHK-152 functioned almost as well, with 50% of animals
surviving (P,0.03). To define the limits of protection in Ifnar2/2
mice, which all succumb to CHIKV between days 3 and 4,
therapy was initiated at 60 and 72 hours after infection. At
60 hours after infection, Ifnar2/2 mice receiving 250 mg each of
CHK-102+CHK-152 or CHK-166+CHK-152 had survival rates
of 28 and 71%, respectively (Fig. 5D, P = 0.03 and P = 0.004).
Nonetheless, when combination therapy was given at 72 hours
after infection, a time when overt disease was present, no survival
benefit was conferred. Thus, combination MAb therapy is superior
to monotherapy in protecting against lethal CHIKV infection in
highly immunocompromised mice.
Functional interaction of MAbs
To begin to understand the basis for enhanced in vivo activity,
we assessed whether CHK-152 and selected MAbs could bind
simultaneously to the CHIKV virion. We developed a competition
ELISA in which virions were captured by a mouse MAb (CHK-
65), and then incubated with increasing concentrations of CHK-
102, CHK-152, CHK-166, or CHK-263 mouse MAbs. After
washing, hu-CHK-152 MAb was added, and binding was
assessed. While pre-bound mouse CHK-152 competed against
hu-CHK-152 binding as expected, CHK-102, CHK-166, and
CHK-263 minimally competed hu-CHK-152 binding (Fig. S5A),
suggesting their epitopes largely were distinct. However, addition
of CHK-102, CHK-166, or CHK-263 failed to augment the
inhibitory activity of CHK-152 when neutralization was measured
in cell culture (Fig. S5B), as no synergy was observed.
Neutralization escape mutants
To identify epitopes targeted by the therapeutic MAbs, we
generated escape mutants in cell culture. After sequential virus
passage under CHK-102, CHK-152, CHK-166, or CHK-263
selection, CHIKV became resistant to neutralization by these
MAbs (Fig. 6A–D). We assessed whether the escape variants
generated in the presence of one MAb remained sensitive to
neutralization by the other MAbs. The CHK-152 escape variant
was neutralized efficiently by CHK-102, CHK-166, and CHK-
263 (Fig. 6B, Table S2 in Text S1, and data not shown), and
analogously the CHK-166 escape variant was inhibited by CHK-
102, CHK-152, and CHK-263 (Fig. 6C, and data not shown). In
contrast, CHK-102 and CHK-263 escape variants reciprocally
were resistant, suggesting their epitopes were the same or
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overlapping (Fig. 6A and D); however, CHK-102 and CHK-263
escape variants remained sensitive to neutralization by CHK-152
and CHK-166. Notably, selection with combinations of MAbs
(e.g., CHK-102+CHK-152) failed to produce escape variants
despite several independent attempts (data not shown).
To identify the mutations that conferred resistance, we
sequenced plaque-purified escape variants (Table 2, top). Six of
eight sequences from CHK-102 escape variants contained an
L210P mutation in the E2 protein; the remaining two
sequences had a G209E mutation in E2. For CHK-152
resistant variants, all sequences (9 of 9) contained a D59N
mutation in E2 and two contained a second A89E substitution
in E2. For CHK-263, 3 of 4 escape variants had a K215E
change in E2, whereas 1 of 4 had mutations in E2 at G209E.
Figure 4. The effector functions of CHK-152 contribute to protection in vivo. A. Comparison of binding of ch-CHK-152 and agylocsyl ch-
CHK-152 N297Q to pE2-E1, as measured by surface plasmon resonance. A single representative sensogram is shown for each MAb. The experimental
curves (colored lines) were fit using a 1:1 Langmuir analysis (dashed lines), after double referencing, to determine the kinetic parameters presented in
the Table immediately below. B. Comparison of neutralizing activity of murine CHK-152, ch-CHK-152, and ch-CHK-152 N297Q, as measured by FRNT
on Vero cells. C. Comparison of binding of ch-CHK-152 and ch-CHK-152 N297Q to FccR (CD16A, 500 nM; CD32A, 100 nM; and CD64, 100 nM) or C1q
(50 nM), as measured by surface plasmon resonance. D. Comparison of pre-exposure protective activity of ch-CHK-152 and ch-CHK-152 N297Q.
Ifnar2/2 mice were administered via an i.p. injection 10 mg of ch-CHK-152 and ch-CHK-152 N297Q one day before infection with 10 FFU of CHIKV-LR
via a s.c. route. Mice were monitored for survival for 21 days after infection. The survival curves were constructed from data of at least two
independent experiments and the number of animals for each antibody ranged from 8 to 10 per group. ch-CHK-152 provided statistically greater
protection than ch-CHK-152 N297Q (P,0.05). E. Five week-old WT C57BL/6 mice were infected with 100 PFU of CHIKV in the left rear footpad and
either sham-treated, or treated with 100, 50, or 25 mg of ch-CHK-152 (left panel) or ch-CHK-152 N297Q (right panel) at 18 hours post infection. Mice
were scored daily for virus-induced footpad swelling, where a score of 0 = no swelling, 1 =mild swelling where the top of the foot is slightly raised,
2 =moderate swelling with the entire top of foot raised, and 3= severe swelling involving both the top and bottom of the foot. Scores are the mean
values for 7 to 8 mice per treatment group and are representative of three independent experiments. Ch-CHK-152 mediated protection was
significantly greater than ch-CHK-152 N297Q on days 7, 8, and 9 post infection for the 100 mg antibody dose, and at day 7 post infection for the 50 mg
dose, as determined by the Kruskal-Wallace test with Bonferroni correction (P,0.05). No statistically significant differences between ch-CHK-152 and
ch-CHK-152 N297Q were observed with the 25 mg dose. Of note, we observed a reproducible decrease in clinical score on day 5 in many animals. This
reflects the biphasic pattern of swelling: during the first 3 to 4 days, swelling is due to edema, whereas after day 5, it is due to inflammatory cell
infiltration into the foot and ankle.
doi:10.1371/journal.ppat.1003312.g004
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All escape variants (14 of 14) of CHK-166 had a single K61T
mutation in the E1 protein.
To verify the amino acid changes that conferred MAb resistance
in vitro, we introduced several of these substitutions into a chimeric
SFV-GFP-CHIKV cDNA comprised of SFV non-structural genes,
a GFP reporter gene, and the CHIKV structural genes (T. Lin, K.
Dowd, and T. Pierson, unpublished results). Parental and SFV-
GFP-CHIKV with single amino acid mutations were analyzed for
neutralization by CHK-102, CHK-152, CHK-166, and CHK-
263 (Fig. 6E–H). Consistent with our sequencing results, viruses
encoding mutations in E2-G209 and E2-L210 were resistant to
CHK-102, changes in E2-D59 conferred resistance to CHK-152,
substitutions in E1-K61 resulted in resistance to CHK-166, and
mutation of E2-G209 and E2-K215 caused resistance to CHK-
263. However, introduction of E2-A89E (which was present in 2 of
9 clones) failed to affect the neutralizing activity of CHK-152.
In addition to selecting escape variants in cell culture, we
harvested organs from the few mice that became ill after infection
Figure 5. Therapeutic efficacy of anti-CHIKV MAbs. A. Ifnar2/2 mice were passively transferred via an i.p. injection 100 mg of DENV1-E98, CHK-
102, CHK-152, CHK-166, or CHK-263 or 50 mg each of CHK-102+CHK-152, CHK-166+CHK-152, CHK-263+CHK-152, or CHK-102+CHK-263 at 24 hours
after CHIKV infection. B. Five week-old WT C57BL/6 mice were infected with 100 PFU of CHIKV in the footpad and either sham-treated, or treated with
100 or 50 mg of CHK-152 at 18 hours post infection. Virus induced pathology in the foot and ankle joint was assessed by histopathological analysis at
day 10 post-infection. (Left) CHIKV-infected, sham-treated, (middle) CHIKV-infected, CHK-152 (100 mg) treated at +18 hours, and (right) CHIKV-infected,
CHK-152 (50 mg) treated at +18 hours. Shown are representative images after hematoxylin and eosin staining from 3 mice per group at 1006
magnification. Yellow and green arrows indicate regions of inflammation or normal joints, respectively. C. Ifnar2/2mice were passively transferred via
an i.p. injection 200 mg of DENV1-E98 or 100 mg each of CHK-102+CHK-152, CHK-166+CHK-152, or CHK-263+CHK-152 at 48 hours after CHIKV
infection. D. Ifnar2/2 mice were passively transferred via an i.p. injection 500 mg of DENV1-E98 or 250 mg each of CHK-102+CHK-152 or CHK-
166+CHK-152 at 60 hours after CHIKV infection. For A, C, and D the survival curves were constructed from data of at least two independent
experiments. The number of animals for each antibody ranged from 8 to 10 per group, with the exception of CHK-102+CHK-263, which was
performed with 7 mice only. Statistically significant differences in protection compared to DENV1-E98 are described in the text.
doi:10.1371/journal.ppat.1003312.g005
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Figure 6. Characterization and mapping of neutralization escape mutants. A–D. FRNT assay with bulk virus obtained after three to six
passages under selection of (A) CHK-102, (B) CHK-152, (C) CHK-166, or (D) CHK-263 on Vero cells. Bulk virus also was tested for infectivity in the
presence of the non-selecting MAbs. Results are representative of two to three independent experiments performed in triplicate. E–H. Confirmation
of resistant phenotype with SFV-CHIKV-GFP containing the indicated single engineered point mutations. Serial dilutions of MAb were incubated with
chimeric SFV-CHIKV virus (WT or mutant stocks) for one hour at room temperature. MAb-virus complexes were added to Vero cells plated in 96-well
plates and incubated at 37uC. After 8 hours cells were trypsinized, fixed, and the number of GFP-positive, infected cells was assessed by flow
cytometry. Curves are representative of 2 to 3 independent experiments. I. Epitope mapping of anti-CHIKV MAbs on the crystal structure of the
mature envelope glycoprotein complex (PDB code 3N44). (Left) The domains on E2 (cyan) and E1 (gold) are indicated, and the fusion loop on E1 (E1
FL) is delineated. Amino acid residues of neutralizing MAbs were determined by escape selection, sequencing, and reverse genetic confirmation.
CHK-102 and CHK-263 recognize the B domain on E2, CHK-152 recognizes a residue on the wings of the A domain on E2, and CHK-166 recognizes an
amino acid in domain II of E1 proximal to the conserved fusion loop. (Right) The mature envelope glycoprotein docked onto the trimer conformation
(PDB code 2XFB) that is present on the virion. E3, E2, and E1 and the escape residues are colored as in the left panel. Neutralization escape residues
are readily accessible on the top of the trimer, distal to the viral membrane.
doi:10.1371/journal.ppat.1003312.g006
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despite single MAb treatment (Table 3, bottom). In these moribund
Ifnar2/2 mice, CHIKV was present in the brain and muscle but
absent from the spleen or liver (data not shown). This in vivo-
derived virus was tested for MAb resistance and sequenced. For
mice receiving a 10 mg dose of CHK-102 as prophylaxis, resistant
variants with a L210P mutation in E2 were obtained. For mice
receiving CHK-263 or CHK-102 at 24 hours post infection,
resistant viruses with a G209E mutation in E2 were identified.
None of the animals that were pre-treated with 10 mg of CHK-166
developed escape mutants, as the virus harvested from all 3 mice
tested retained sensitivity to CHK-166 (data not shown). However,
in one animal receiving CHK-166 at 24 hours post infection, a
single resistant virus with a G64S substitution in the E1 gene was
recovered (Fig. S6). For mice receiving a 10 mg dose of hu-CHK-
152 as prophylaxis, partially resistant viruses with N231D and
K233E mutations in E2 were isolated and confirmed by reverse
genetics using the chimeric SFV-GFP-CHIKV infectious clone
(Fig. S7). In comparison, when CHK-152 was given as a
therapeutic, a single mutation at D59N in E2 was obtained in 4
of the 5 mice tested, with a K233T mutation in virus from the
remaining animal. For animals treated at 48 hours with combi-
nation MAb therapy, all recovered viruses remained sensitive to
CHK-152 yet showed partial resistance to CHK-102 or CHK-166
(Fig. S8). Mutations in E2 (N332I, CHK-166+CHK-152) were
identified. Comparison of 140 available E1 and E2 sequences from
historical and circulating CHIKV strains in a public database
(http://www.viprbrc.org/) revealed nearly complete conservation
of the residues in which escape mutants were selected: E1-K61,
100%; E1-G64, 100%; E2-D59, 100%; E2-G209, 100%; E2-
L210, 99.3%; E2-K215, 100%; E2-N231, 100%; and E2-K233,
99.3%.
To define spatially the location of the amino acids that
conferred resistance to our highly protective MAbs, these residues
were mapped onto the existing CHIKV protein crystal structures
[10] (Fig. 6I, left). Amino acids that conferred neutralization
escape to CHK-102 and CHK-263 were located in the B domain
of E2. The residues that modulated CHK-152 neutralization
mapped to the A domain of E2. In contrast, CHK-166 recognized
amino acids on DII of E1, adjacent to the fusion loop. All amino
acids that conferred neutralization escape appear solvent accessi-
ble and highly exposed when docked onto the E2-E1 spike
(Fig. 6I, right).
Discussion
We set out to identify MAbs with the greatest therapeutic
activity against CHIKV in mice as a first step toward generating
an immunotherapy for humans. Thirty-six MAbs with neutralizing
activity against CHIKV-LR were identified, the majority of which
also inhibited infection of strains corresponding to the two
heterologous CHIKV genotypes. Although all fourteen of the
selected anti-CHIKV MAbs improved outcome in vulnerable
Ifnar2/2 mice, only four of these (CHK-102, CHK-152, CHK-
166, and CHK-263) completely prevented lethality when admin-
istered as prophylaxis. CHK-152 provided the greatest benefit as
post-exposure therapy, although by itself, the window of treatment
activity was limited in the Ifnar2/2 mouse model. While addition
of a second MAb (CHK-102, CHK-166, or CHK-263) failed to
enhance CHK-152 neutralization in vitro, it limited the develop-
ment of viral resistance in vitro and in vivo. Remarkably,
combinations of CHK-102+CHK-152 or CHK-166+CHK-152
protected Ifnar2/2 mice against mortality even when a single dose
was administered 24 to 36 hours prior to the death of untreated or
isotype control MAb-treated animals.
In comparison to the highly therapeutic activity of 0.5 mg of
CHK-152+CHK-166, a single 25 mg dose of immune IgG
purified from a convalescent human subject protected only 50%
of Ifnar2/2 mice when administered 24 hours after CHIKV
infection [26]. The administered dose of neutralizing antibody
likely is critical to post-exposure treatment of CHIKV infection
because of the high viral burden [14,16,17,40]. A high viral load
impacts therapeutic activity of antibodies as it (a) increases the
chance for pre-existing or selected resistant variants to emerge
through quasispecies [28,41]; and (b) results in a low relative
fractional occupancy of binding to any individual virion, which
allows antibodies recognizing key epitopes to fall below their
stoichiometric threshold of neutralization [42]. Although there is
extensive literature on the protective efficacy of MAbs or immune
sera against alphavirus infection [18–25], no prior study has
demonstrated reduced CHIKV-induced mortality with MAbs.
Table 2. In vitro selection of viruses resistant to MAb
neutralization.
MAb Mutationa # of plaque picks
CHK-102 E2: L210P 6 of 8
CHK-102 E2: G209E 2 of 8
CHK-152 E2: D59N 9 of 9
CHK-152 E2: A89Eb 2 of 9
CHK-166 E1: K61T 14 of 14
CHK-263 E2: K215E 3 of 4
CHK-263 E2: G209E 1 of 4
aIn vitro selection for neutralization escape variants was performed by
passaging CHIKV-LR in the presence of 25 mg/ml of the indicated MAbs.
Resistant virus was isolated at passage 3 (CHK-102, CHK-152, and CHK-263) or
passage 6 (CHK-166), plaque purified, and sequenced.
bThe A89E mutant was identified after sequencing of CHK-152 escape mutants
in cell culture, but was determined to be insignificant for CHK-152
neutralization by reverse genetic analysis (see Fig. 6F).
doi:10.1371/journal.ppat.1003312.t002





CHK-102 224 h, 10 mg 11R.10,000 E2: L210P
CHK-102 +24 h, 100 mg 11R.10,000 E2: G209E
CHK-152 224 h, 10 mg 2R10,000 E2: N231D
E2: K233E
CHK-152 224 h, 10 mg 2R3,000 E2: K233E
CHK-152 +24 h, 100 mg 2R.10,000 E2: D59N
CHK-152 +24 h, 100 mg 2R.10,000 E2: K233T
CHK-166 +24 h, 100 mg 170R.10,000 E1: G64S
CHK-263 +24 h, 100 mg 5R.10,000 E2: G209E
CHK-166+CHK-152 +48 h, 250 mg CHK-166: 170R540 E2: N332I
CHK-152: 2R2.6
aIn vivo selection for resistant virus was performed by administering the
indicated individual or combinations of MAbs before (224 hours) or after (+24
or 48 hours) CHIKV-LR infection. Resistant virus was isolated directly from
tissues (leg and brain), and cDNA was prepared by reverse transcription and
sequenced. The change in neutralizing activity of the bulk virus recovered from
tissue is highlighted by the differences in EC50 values.
doi:10.1371/journal.ppat.1003312.t003
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Although a recent study showed that combination post-exposure
therapy with two human anti-CHIKV MAbs (5F10 and 8B10,
250 mg each at +8 h) prolonged survival of AG129 (Ifnar2/
26Ifngr2/2) mice by ten days, they failed to prevent lethal
infection [29]; the basis of this treatment failure remains unclear
but could reflect the lower neutralizing potency of the MAbs
(compared to CHK-152), rapid emergence of resistant mutants, or
the relative susceptibility of the immunocompromised mouse host.
In comparison, a neutralizing MAb (UM 5.1) administered two
days after SFV infection completely protected immunocompetent
BALB/c mice [43].
Why were some combinations of two MAbs effective in vivo? (a)
Pairs of MAbs may show neutral, additive, or synergistic effects on
neutralization. Positive antiviral effects could occur through
cooperative binding or by trapping CHIKV in conformations
that makes it less competent to bind a receptor or fuse with host
membranes. Nonetheless, when we added increasing concentra-
tions of CHK-102, CHK-166, or CHK-263 to CHK-152, we
failed to observe synergy. (b) Certain MAb combinations could
prevent the emergence of resistance due to the low frequency of
two escape mutations occurring simultaneously in a single
replication cycle. Although we could readily select for neutraliza-
tion escape against a single MAb in vitro and in vivo, we failed to
isolate resistant mutants against CHK-152 when two MAbs (e.g.,
CHK-102+CHK-152) were combined. However, some viruses
from moribund animals treated with combination MAb therapy
showed reduced sensitivity (up to 200-fold) to the other MAb (e.g.,
CHK-102) in the pair. In comparison, when mice were treated
with a combination of 50 mg each of CHK-102+CHK-263, we
failed to observe the same survival benefit that was conferred by
the combinations of CHK-102, CHK-166, or CHK-263 with
CHK-152. Since CHK-102 and CHK-263 appear to share
overlapping footprints on domain B of E2, this particular MAb
combination may fail to prevent the rapid emergence of escape
mutants relative to others targeting distinct epitopes on E1 and E2
proteins. (c) Combinations of MAbs could select for resistant
viruses that have reduced fitness [44], and thus are less pathogenic
in vivo. Virulence studies with CHIKV encoding selected single and
double mutations are planned to evaluate this possibility.
We localized the epitopes of our four highly protective MAbs
using neutralization escape selection, sequencing, and reverse
genetics. CHK-152, which blocked viral fusion, mapped to the
wings of the A domain on E2, a result that we recently confirmed
by cryo-electron microscopic analysis of CHK-152 Fab-virus
particle complexes [45]. This epitope also was identified as a
recognition site for neutralizing MAbs against VEEV [46] and
SINV [47]. CHK-166, which was the least neutralizing (EC50 of
,100 ng/ml) of our highly protective MAbs mapped to an epitope
in domain II of the E1 protein, adjacent to the highly conserved
fusion loop. While anti-E1 MAbs against SINV and VEEV that
protect or neutralize infection have been described [46,48,49],
none have been characterized against CHIKV. A neutralizing
human MAb (8B10) against CHIKV was reported with possible
reactivity against E1, although further analysis revealed that it
bound to the E1/E2 heterodimer [27,28]. CHK-102 and CHK-
263 mapped to residues within the B domain on E2. A related
epitope also was identified in mapping studies of strongly
neutralizing antibodies against Ross River virus [50], SINV
[51,52], VEEV [46,53,54], and CHIKV [10,28]. The B domain
on E2 comprises an important antigenic domain that is under
selective pressure for antibody neutralization [41]. It serves as a
cap to the fusion loop on E1 and because of its location at the tip of
the heterodimeric spike [10,11] may contribute to attachment of
cellular receptors.
In summary, we identified combinations of MAb pairs that were
highly effective as post-exposure therapeutic agents. These findings
are consistent with recent studies showing enhanced post-exposure
efficacy of MAb combinations against Ebola [55], influenza A [56]
and rabies [57] viruses. Our most promising pair of MAbs mapped
to distinct epitopes, limited the generation of resistance, blocked
multiple stages of the viral entry pathway, and protected Ifnar2/2
mice against mortality even when administered 60 hours after
infection. CHK-152 was humanized as a first step towards a
possible therapeutic for humans and demonstrated similar efficacy
compared to the parent murine MAb. Tailored combinations of
potently neutralizing MAbs show promise to prevent or treat
infection by CHIKV, and likely other pathogenic alphaviruses in
humans. Ultimately, a more detailed kinetic analysis of CHIKV
infection in humans and determination of a treatment window
relative to symptom onset is warranted to establish whether
combination MAb therapy can prevent or mitigate acute or
chronic and persistent infection and joint disease.
Methods
Cells and viruses
Vero, Vero76 (ATCC), BHK21-15, and NIH 3T3 mouse
fibroblast cells were cultured in Dulbecco’s modified Eagle
medium (DMEM) supplemented with 5% or 15% (for 3T3 cells)
fetal bovine serum (FBS) (Omega Scientific). C6/36 Aedes albopictus
cells were grown in Leibovitz-15 medium supplemented with 10%
FBS at 27uC. The infectious clones of CHIKV La Reunion 2006
OPY-1 (strain 142, CHIKV-LR) and CHIKV-GFP (strain 145)
were gifts from S. Higgs (Manhattan, KS) [58]. CHIKV-RSU1
and CHIKV-IbH35 were gifts of R. Tesh, (Galveston, TX).
Infection studies of WT mice used the SL15649 strain of CHIKV,
which was generated from an infectious clone [17]. The S27
African prototype CHIKV strain was a gift from Dr. S. Gu¨nther
(Bernhard-Nocht-Institute for Tropical Medicine, Germany) and
isolated from a patient in Tanzania in 1953.
Ethics statement
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. The
protocols were approved by the Institutional Animal Care and Use
Committee at the Washington University School of Medicine
(Assurance Number: A3381-01) and the University of North
Carolina (A3410-04). Dissections and footpad injections were
performed under anesthesia that was induced and maintained with
ketamine hydrochloride and xylazine, and all efforts were made to
minimize suffering.
Generation of chimeric SFV-CHIKV
Chimeric SFV-CHIKV virus was generated by complementa-
tion of a double sub-genomic DNA-launched SFV replicon
‘‘backbone’’ plasmid (pSFV-GFP-BB) with the structural genes
of CHIKV as described recently for WNV [59]. The vectors and
methods will be described in detail elsewhere (TY Lin, K. Dowd,
and T. Pierson, in preparation). To generate SFV-CHIKV, a
DNA fragment encoding WT or mutant CHIKV structural genes
was ligated into the pSFV-GFP-BB plasmid and transfected
directly into HEK-293T cells using Lipofectamine LTX. The
source of CHIKV structural genes was a sub-cloning vector
pCHIKV-struct: mutations were introduced into this vector using
site-directed mutagenesis and fully sequenced. Virus was harvested
at 48, 72, or 96 hours after transfection, filtered, and stored at
280uC.
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CHIKV protein
The CHIKV E2 ectodomain (residues S1-E361) and pE2-E1
(E3-E2-E1: residues S1-R64 of E3, S1-E161 of E2, and Y1-Q411
of E1 including a (GGGS)4 polylinker between E2 and E1) of the
CHIKV-LR strain were amplified from the infectious cDNA clone
using high-fidelity Phusion PCR (Thermo Scientific). The E2
ectodomain was cloned into pET21a, expressed in E. coli, and
purified using an oxidative refolding protocol followed by size-
exclusion column purification using fast protein liquid chroma-
tography [60]. pE2-E1 was cloned into the mammalian expression
vector pHLsec (Invitrogen) with a C-terminal octa-histidine tag
and modified to express the Epstein–Barr virus EBNA-1 protein
for enhanced protein expression. pE2-E1 was expressed in serum-
free HEK-293F suspension cells and purified by Ni-NTA agarose
affinity (Qiagen) and Superdex 200 gel filtration chromatography.
MAb generation
Irf72/2 mice were infected and boosted with 104 PFU of
CHIKV-LR and, depending on the experiment, given a final
intravenous (i.v.) boost with CHIKV virus-like particles [30],
25 mg of E2 protein, or 26105 PFU of CHIKV-LR three days
prior to fusion with myeloma cells. Hybridomas secreting
antibodies that reacted with CHIKV-GFP-infected BHK21-15
cells were identified by flow cytometry and cloned by limiting
dilution. MAbs were isotyped by ELISA (Pierce), adapted for
growth under serum-free conditions, and purified by protein G
affinity and size exclusion chromatography. All MAbs were
screened initially with a single endpoint neutralization assay using
neat hybridoma supernatant (,10 mg/ml), which was incubated
with 100 FFU of CHIKV-LR for one hour at 37uC. MAb-virus
complexes were added to BHK21-15 cell monolayers in 6-well
plates. After 90 minutes, cells were overlaid with 1% (w/v) agarose
in Modified Eagle Media (MEM) supplemented with 4% FBS.
Plates were fixed with 10% formaldehyde in PBS 48 hours later,
stained with crystal violet, and plaques were counted. The VH and
VL sequence of neutralizing MAbs CHK-102, CHK-152, CHK-
166, and CHK-263 were amplified from hybridoma cell RNA by
a 59 RACE procedure Table S3 in Text S1).
Chimerization of MAbs
The generation of a chimeric mouse-human CHK-9 and CHK-
152 with mouse VH and VL and human IgG1 constant regions was
performed as described previously [60]. A point mutation that
abolishes FccR and C1q binding (N297Q) was introduced by
QuikChange mutagenesis (Stratagene). Recombinant antibodies
were produced after transfection of HEK-293T cells, harvesting of
supernatant, and purification by protein A affinity chromatogra-
phy.
Infection of mice
(a) Immunocompromised mice. Ifnar2/2 mice were bred
in pathogen-free animal facilities of the Washington University
School of Medicine and infection experiments were performed in
A-BSL3 facilities with the approval of the Washington University
Animal Studies Committee. For prophylaxis studies, MAbs were
administered by i.p. injection to 6 to 8 week-old Ifnar2/2 mice one
day prior to s.c. infection in the footpad with 10 FFU of CHIKV-
LR. For therapeutic studies, 10 FFU of CHIKV-LR was delivered
24, 48, 60, or 72 hours prior to administration of a single dose of
individual or combinations of MAbs. To monitor viral burden in
vivo, mice were treated with a single 100 mg dose of anti-CHK or
isotype control MAb one day before infection with 10 FFU of
CHIKV-LR. Animals were sacrificed two days later for virological
analysis. After extensive perfusion with PBS, organs were
harvested, weighed, homogenized and virus was titered by focus-
forming assay.
(b) Immunocompetent mice. Four to six week-old C57BL/
6 mice were infected s.c. in the footpad with 100 PFU of CHIKV
SL15649 in 10 ml of PBS as described previously [17]. Some
animals received 100 mg of MAb in 500 ml of PBS via an i.p. route
before or after infection. Mice were monitored daily for footpad
swelling. At 10 days after infection, mice were sacrificed and
sections prepared from decalcified hind limbs [17] for histopath-
ological analysis. All CHIKV studies with WT mice were
performed under A-BSL-3 conditions and in accordance with
approved protocols following University of North Carolina
guidelines.
Neutralization assays
Serial dilutions of MAb were incubated with 100 FFU of
CHIKV for one hour at 37uC. MAb-virus complexes were added
to cells in 96-well plates. After 90 minutes, cells were overlaid with
1% (w/v) methylcellulose in Modified Eagle Media (MEM)
supplemented with 4% FBS. Plates were harvested 18 to 24 hours
later, and fixed with 1% PFA in PBS. The plates were incubated
sequentially with 500 ng/ml of ch-CHK-9 and horseradish
peroxidase (HRP)-conjugated goat anti-human IgG in PBS
supplemented with 0.1% saponin and 0.1% BSA. CHIKV-
infected foci were visualized using TrueBlue peroxidase substrate
(KPL) and quantitated on an ImmunoSpot 5.0.37 macroanalyzer
(Cellular Technologies Ltd). Non-linear regression analysis was
performed, and EC50 values were calculated after comparison to
wells infected with CHIKV in the absence of antibody.
Pre- and post-attachment neutralization assays
96-well tissue culture plates were coated with 100 ml of poly-L
lysine and seeded with 36104 Vero cells/well overnight. For pre-
attachment assays, dilutions of MAb were prepared at 4uC in
DMEM with 2% FBS and pre-incubated with 100 FFU of
CHIKV-LR for one hour at 4uC. MAb-virus complexes were
added to pre-chilled Vero cells for one hour at 4uC. Non-adsorbed
virus was removed with three washes of DMEM and adsorbed
virus was allowed to internalize during a 37uC incubation for
15 minutes. Cells were overlaid with 1% (w/v) methylcellulose in
MEM supplemented with 4% FBS. The post-attachment assay
was performed similarly, except that an equivalent amount of
CHIKV was adsorbed first onto Vero cells for one hour at 4uC.
After removing free virus, dilutions of MAb were added to the
virus-adsorbed cells for one hour at 4uC. Virus was allowed to
internalize and cells were overlaid with methylcellulose as
described above. Nineteen hours later, the plates were harvested
and analyzed for antigen-specific foci as described above.
Fusion inhibition assays
(a) Fusion from without assay. Virus fusion with the
plasma membrane was assessed using a fusion from without
(FFWO) assay [36]. Vero cells were seeded in 96-well plates,
washed once with Binding medium (RPMI 1640, 0.2% BSA,
10 mM HEPES pH 7.4, and 20 mM NH4Cl) at 4uC, and
incubated for 15 minutes at 4uC. CHIKV-LR (MOI of 15) was
prepared in Binding medium and added to cells for one hour at
4uC, and then free virus was removed. Subsequently, DMEM
containing 2% FBS with or without CHIKV-specific or control
MAbs (50 mg/ml) was added to cells for one hour at 4uC. FFWO
was induced by the addition of pre-warmed fusion media (RPMI
1640, 0.2% BSA, 10 mM HEPES, and 30 mM succinic acid at
pH 5.5) for two minutes at 37uC. In parallel wells, control media
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(RPMI 1640, 0.2% BSA, 10 mM HEPES at pH 7.4) was added
for 2 minutes at 37uC to ensure that infection occurred only
through pH-dependent plasma membrane fusion. Medium was
removed and cells were incubated in DMEM supplemented with
5% FBS, 10 mM HEPES, and 20 mM NH4Cl (pH 7.4); NH4Cl
prevented secondary infection through endosomal fusion path-
ways. Cells were detached 14 hours later, fixed with 1% PFA in
PBS for 8 minutes, and permeabilized with 0.1% (w/v) saponin
detergent solution. Cells were incubated sequentially with ch-
CHK-9 and Alexa 647 conjugated goat anti-human IgG
secondary antibody (Invitrogen). Infection was evaluated on a
FACSArray flow cytometer (Becton-Dickinson) and analyzed
using FlowJo software.
(b) Liposomal fusion assay. Pyrene-labeled CHIKV (S27
African strain) was recovered from supernatants of infected
Vero76 cells cultured for 48 hours in the presence of 15 mg/ml
16-(1-pyrenyl)hexadecanoic acid (Invitrogen) as described [37].
Fusion of pyrene-labeled CHIKV with liposomes was monitored
continuously in a Fluorolog 3–22 fluorometer (BFi Optilas),
essentially as described [37]. Pyrene-labeled CHIKV and an
excess of liposomes were mixed in a final volume of 665 ml in
5 mM HEPES, 150 mM NaCl, 0.1 mM EDTA, pH 7.4. Fusion
was triggered by the addition of 35 ml 0.1 M MES, 0.2 M acetic
acid, which achieved a pH of 4.7. For the antibody inhibition
experiments, pyrene-labeled CHIKV was incubated with increas-
ing concentrations of CHIKV-152 or isotype control IgG2a MAb
(MAb 0031, R&D systems) for 10 minutes at 37uC prior to mixing
with liposomes.
SPR
The binding of human FccR and C1q to ch-CHK-152 and ch-
CHK-152 (N297Q) was analyzed by SPR using a BIAcore 3000
biosensor (GE Healthcare Life Sciences). MAbs were captured
(,900 RU) after flowing over immobilized F(ab)92 fragments of
goat anti-human F(ab)92 specific IgG on a CM-5 sensor chip.
Binding experiments were performed in HBS-EP buffer (10 mM
Hepes, pH 7.4, 150 mM NaCl, 3 mM EDTA, and 0.005% P20
surfactant). Binding of CD16A and CD64 (as monomeric soluble
FccR), CD32A (as dimeric soluble FccR-aglycosylated Fc fusion),
and C1q (Sigma-Aldrich) was analyzed at a single concentration.
The FccR and C1q were injected for 60 sec at a flow rate of
30 ml/min then allowed to dissociate over 2 minutes. Affinity
measurements of CHK-152 MAbs for pE2-E1 were performed by
SPR in HBS-EP buffer. Ch-CHK-152, ch-CHK-152 N297Q, hu-
CHK-152 and mouse CHK-152 were captured (,300 RU) after
flowing over immobilized F(ab)92 fragments of goat anti-human or
anti-mouse Fc specific IgG. Purified pE2-E1 was injected at
concentrations of 0, 6.25, 12.5, 25, 50, and 100 nM, at a flow rate
of 30 ml/min for 120 sec, and then allowed to dissociate over
2 minutes. Regeneration of capture surfaces was performed by
pulse injection of 10 mM glycine pH 1.5. Binding curve at the
zero concentration of pE2-E1 was subtracted from each experi-
mental curve as a blank. Data were analyzed using BIAevaluation
4.1 software. Kinetic constants, ka and kd, were estimated by
global fitting analysis of the association/dissociation curves to the
1:1 Langmuir interaction model.
Escape mutant selection
CHIKV-LR (1.26105 FFU) was incubated with 25 mg/ml of
MAbs for one hour at 37uC. Virus-MAb complexes were added to
Vero cells and infection proceeded for 24 hours. At each passage,
half of the supernatant was mixed (1:1) with 50 mg/ml of the
selection MAb for one hour at 37uC. These complexes were added
to a new monolayer of Vero cells for 2 hours, and the procedure
was repeated from 3 to 6 times depending on the selection MAb.
Individual MAb-resistant viral plaques were picked and virus was
grown in Vero cells in the presence of 10 mg/ml of MAb for
24 hours. RNA was isolated from cells using an RNeasy kit
(Qiagen) and cDNA was made with random hexamers using the
Superscript III Reverse Transcriptase kit (Invitrogen) and ampli-
fied by PCR with primers flanking the structural genes (Table
S4). The PCR product was sequenced using ten overlapping
primer sets (Table S4).
Mapping of mutations onto the CHIKV p62-E1 crystal
structure
Figures were prepared using the atomic coordinates of CHIKV
pE2-E1 (RCSB accession number 3N44) using the program
CCP4MG [61].
Statistical analysis
For survival analysis, Kaplan-Meier survival curves were
analyzed by the log-rank test. For growth kinetics and neutrali-
zation an unpaired T-test or analysis of variance was used to
determine significance. These analyses were assessed using Prism
software (GraphPad software). The protective effects of ch-CHK-
152 versus ch-CHK-152 N297Q in wild type C57BL/6 mice were
analyzed by the Kruskal-Wallace test with Bonferroni correction
using the agricolae package of R (R Development Core Team,
2010. Foundation for Statistical Computing, Vienna, Austria).
Supporting Information
Figure S1 Screening of hybridoma supernatants for
binding to CHIKV-infected cells. Hybridoma supernatants
were incubated with CHIKV-GFP infected BHK21 cells and
tested for immunoreactivity by flow cytometry. Shown are
examples of a negative control MAb (DENV3-E2), three ‘hits’
(later named as CHK-102, CHK-117, and CHK-130), and a
negative supernatant (5E3). The y-axis shows GFP staining
associated with the reporter gene that is translated from the
subgenomic promoter of CHIKV, and the x-axis shows staining of
the tested mouse MAb. Double-positive cells were considered ‘hits’
in the screen. The result is representative of many different MAbs
performed in the original screen.
(TIF)
Figure S2 Binding kinetics of CHK-MAbs to pE2-E1.
Binding curves and kinetic parameters of pE2-E1 binding to
mouse CHK-102, CHK-152, CHK-166, and CHK-263 MAbs. A
single representative sensogram is shown for each MAb. The
experimental curves (colored lines) were fit using a 1:1 Langmuir
analysis (dashed lines), after double referencing, to determine the
kinetic parameters presented immediately below.
(TIF)
Figure S3 Pre- and post-attachment neutralization as-
says. Vero cells were pre-chilled to 4uC and 100 FFU of CHIKV-
LR was added to each well for one hour at 4uC. After extensive
washing at 4uC, the indicated MAbs (CHK-48, CHK-65, CHK-95,
CHK-112, CHK-124, CHK-142, CHK-155, CHK-175, CHK-84
and DENV1-E98) were added for one hour at 4uC, and then the
FRNT protocol was completed (black lines, Post). In comparison, a
standard pre-incubation FRNT with all steps performed at 4uC is
shown for reference. Virus and MAb are incubated together for one
hour at 4uC, prior to addition to cells (red lines, Pre). Data shown are
representative of three experiments performed in duplicate with
error bars representing standard deviation.
(TIF)
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Figure S4 Construction and efficacy of humanized
CHK-152. We amplified the cDNA encoding the heavy (VH)
and light (VL) variable domains from the hybridoma cellular RNA
and grafted the complementarity determining regions onto the
human VH1-18 and human Vk-L6 backbones. The resulting
humanized VH and VL were combined with human c1 and k
constant regions, fused to an IgG signal sequence, expressed in
293T cells and purified (data not shown). A. Binding curves and
kinetic parameters of pE2-E1 binding to mouse CHK-152 and hu-
CHK-152. A single representative sensogram is shown for each
MAb. The experimental curves (colored lines) were fit using a 1:1
Langmuir analysis (dashed lines), after double referencing, to
determine the kinetic parameters presented in the Table immedi-
ately below. B. Neutralization studies with mouse CHK-152 and
hu-CHK-152. Neutralizing activity was determined by FRNT assay
on Vero cells. Samples were performed in duplicate and the
experiment is one representative of three. C. Pre-exposure
protective activity of hu-CHK-152. Ifnar2/2 mice were passively
transferred via an i.p. injection 10 or 100 mg of mouse hu-CHK-152
one day before CHIKV infection. Mice were monitored for survival
for 21 days after infection. The survival curves were constructed
from data of at least two independent experiments and the number
of animals for each antibody ranged from 8 to 10 per group.
(TIF)
Figure S5 Interaction of neutralizing MAbs. A. Virion
capture ELISA and competition of MAb binding. 96-well plates
were coated with 5 mg/ml of CHK-65 MAb. Non-specific binding
sites were blocked, and 36106 FFU of CHIKV 181-25 was
captured. Subsequently, plates were incubated with the indicated
anti-CHK mouse MAbs (CHK-102, CHK-152, CHK-166, or
CHK-263) or controls (no MAb, PBS; irrelevant MAb, WNV E28)
for one hour. After washing, plates were incubated sequentially
with 125 ng/ml hu-CHK-152 and biotin-labeled goat anti-human
secondary antibody. After washing and incubation with HRP-
conjugated streptavidin, plates were developed and emission
(450 nm) was read using an iMark microplate reader (Bio-Rad).
Results are representative of three independent experiments, each
performed in triplicate. B. Neutralizing activity of MAb
combinations. Increasing concentrations of individual MAbs
(CHK-102, CHK-152, CHK-166, and CHK-263) or combina-
tions of MAbs (CHK-102+CHK-152, CHK 102+CHK-263,
CHK-152+CHK-166, or CHK-152+CHK-263) were mixed with
100 FFU of CHIKV-LR for one 1 hour at 37uC and Vero cells
were infected. Neutralization was determined by FFU assay. Data
is representative of three independent experiments performed in
duplicate.
(TIF)
Figure S6 Selection of escape E1-G64S escape mutant in
vivo against CHK-166. Ifnar2/2 mice were infected with
CHIKV and 24 hours later administered a single 100 mg dose of
CHK-166. Six days later, virus was recovered from the
contralateral leg and brain from one moribund mouse and the
structural genes were sequenced. Both viral isolates recovered
showed a single point G64S mutation in the E1 gene. This isolate
was tested for neutralization by CHK-102 (EC50 of 161 ng/ml),
CHK-152 (EC50 of 2 ng/ml), CHK-166 (EC50.10,000 ng/ml)
and CHK-263 (25 ng/ml). Data is the average of two independent
experiments performed in triplicate.
(TIF)
Figure S7 Confirmation of neutralization escape mu-
tants selected in vivo. Confirmation of resistant phenotype
selected with CHK-152 in vivo using SFV-CHIKV-GFP contain-
ing the indicated single engineered point mutations. Serial
dilutions of CHK-152, CHK-102, and CHK-263 were incubated
with chimeric SFV-CHIKV virus (WT or mutant stocks) for one
hour at room temperature. MAb-virus complexes were added to
Vero cells plated in 96-well plates and incubated at 37uC. After
8 hours cells were trypsinized, fixed, and the number of GFP-
positive infected cells was assessed by flow cytometry. Curves are
representative of 2 independent experiments.
(TIF)
Figure S8 Relative resistance of CHIKV recovered from
mice after treatment with combination MAb therapy.
Ifnar2/2 mice were infected with CHIKV and 48 hours later given
a single dose of combination MAb (CHK-102+CHK-152 or
CHK-166+CHK-152) therapy. Virus was recovered from the
contralateral leg and/or brain from the few moribund mice and
the structural genes were sequenced. Two viral isolates showed
differences in neutralization patterns that corresponded to amino
acid substitutions (see Table 2). Neutralization analysis of these
viruses recovered from animals treated with (left) CHK-102 and
CHK-152 or (right) CHK-166 and CHK-152 and tested against
the respective MAbs. A comparison with the parent virus is shown.
The curves are representative of two independent experiments
performed in triplicate, and error bars indicate standard
deviations.
(TIF)
Text S1 Supplemental Methods and Tables S1–S4.
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